Ovarian Cancer Canada

Western Regional Blog – BC, YK, AB, NWT and Nunavut

RNF43 mutations are recurrent in Chinese patients with mucinous ovarian carcinoma…

“Survival and Quality of Life after neo-adjuvant chemotherapy followed by surgery was similar to survival and QOL after primary debulking surgery followed by chemotherapy. However, institutions with good QOL compliance had better survival outcomes.”

RNF43 mutations are recurrent in Chinese patients with mucinous ovarian carcinoma but absent in other subtypes of ovarian cancer.


Ring finger protein 43 (RNF43) is an E3 ubiquitin-protein ligase that accepts ubiquitin from an E2 ubiquitin-conjugating enzyme and directly transfers the ubiquitin to targeted substrate proteins. Recently, large-scale sequencing efforts have identified prevalent RNF43 mutations in pancreatic and ovarian mucinous carcinomas. In the present study, we sequenced the entire coding sequences of RNF43 in 251 Chinese patients with distinct subtypes of ovarian cancers for the presence of RNF43 mutations. A total of 2 novel heterozygous nonsynonymous RNF43 mutations were identified in 2 out of 15 (13.3%) patients with mucinous ovarian carcinoma, these mutations were evolutionarily highly conserved; while no mutation was detected in other samples. In addition, none of the RNF43-mutated samples harbored DICER1 (dicer 1, ribonuclease type III), PPP2R1A (protein phosphatase 2, regulatory subunit A, alpha), TRRAP (transformation/transcription domain-associated protein) and DNMT3A (DNA (cytosine-5-)-methyltransferase 3 alpha) hot-spot mutations. Recurrent RNF43 mutations existed in mucinous ovarian carcinomas implicated that these mutations might play crucial roles in the tumorigenesis of these patients, while the absence of DICER1, PPP2R1A, TRRAP and DNMT3A hot-spot mutations suggested that these genetic alterations might not play synergistic roles with RNF43 mutations in these individuals. Additionally, the absence of RNF43 mutations in other subtypes of ovarian carcinoma implicated that RNF43 mutations might not be actively involved in the pathogenesis of these disorders.

Zou Y, Wang F, Liu FY, Huang MZ, Li W, Yuan XQ, Huang OP, He M.


This entry was posted on September 16, 2013 by in Research Updates.

Complementary and Alternative Therapies


Research in BC

The Injustices of Ovarian Cancer

Ovarian Cancer Canada

%d bloggers like this: